A randomized phase II trial comparing every 3-weeks carboplatin/paclitaxel with every 3-weeks carboplatin and weekly paclitaxel in advanced non-small cell lung cancer

Annals of Oncology

Volumn 17, Issue 1, 2006, Pages 104-109

  Socinski, M A ^a   Ivanova, A ^a   Bakri, K ^a   Wall, J ^a   Baggstrom, M Q ^a   Hensing, T A ^b   Mears, A ^a   Tynan, M ^a   Beaumont, J ^b   Peterman, A H ^b   Niell, H B ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Carboplatin; Non small cell lung cancer; Paclitaxel

Indexed keywords

CARBOPLATIN; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTHRALGIA; ARTICLE; BLOOD TOXICITY; CANCER STAGING; CANCER SURVIVAL; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG RESPONSE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; VOMITING;

EID: 29844433092     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdj016     Document Type: Article

References (21)

1. American Cancer Society. Cancer Facts and Figures. 2004. http://www.cancer.org
2. Socinski MA. Chemotherapy for stage IV non-small cell lung cancer. In Detterbeck FC, Rivera MP, Socinski MA, Rosenman JG (eds): Diagnosis and Treatment of Lung Cancer: An Evidence-Based Guide for the Practicing Clinician. Philadelphia, PA: WB Saunders 2001; 307-325.
3. Pfister DG, Johnson DH, Azzoli CG et al. American Society of Clinical Oncology Treatment of Unresectable Non-Small Cell Lung Cancer Guideline: Update 2003. J Clin Oncol 2004; 22: 330-353.
4. Schiller J, Harrington D, Belani C et al. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 2002; 346: 92-98.
5. Scagliotti G, De Marinis F, Rinaldi M et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small cell lung cancer. J Clin Oncol 2002; 20: 4285-4291.
6. Kelly K, Crowley J, Bunn PA Jr et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non small-cell lung cancer: A Southwest Oncology Group trial. J Clin Oncol 2001; 19: 3210-3218.
7. Reshkin SJ, Bellizzi A, Cardone RA et al. Paclitaxel induces apoptosis via protein kinase A- and p38 mitogen-activated protein-dependent inhibition of the Na(+)/H(+) exchanger (NHE) NHE isoform 1 in human breast cancer cells. Clin Cancer Res 2003; 9: 2366-2373.
8. Lanni JS, Lowe SW, Licitra EJ et al. p53-independent apoptosis induced by paclitaxel through an indirect mechanism. Proc Natl Acad Sci USA 1997; 94: 9679-9683.
9. Belani CP, Barstis J, Perry MC et al. Multicenter, randomized trial for stage IIIB or IV non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation. J Clin Oncol 2003; 21: 2933-2939.
10. Belani C, Larocca R, Rinaldi D et al. A multicenter, phase III randomized trial for stage IIIB/IV NSCLC of weekly paclitaxel and carboplatin vs. standard paclitaxel and carboplatin given every three weeks, followed by weekly paclitaxel. Proc Am Soc Clin Oncol 2004; 23: 619.
11. Socinski MA, Schell MJ, Peterman A et al. Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. J Clin Oncol 2002; 20: 1335-1343.
12. Calvert A, Newell D, Gumbrell L et al. Carboplatin dosage: Prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989; 7: 1748-1756.
13. Cella D, Tulsky D, Gray G. The functional assessment of cancer therapy scale: Development and validation of the general measure. J Clin Oncol 1993; 11: 570-579.
14. Cella D, Bonomi A, Lloyd S et al. Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument. Lung Cancer 1995; 12: 199-200.
15. Cella D, Peterman A, Hudgens S et al. Measuring the side effects of taxane therapy in oncology: The functional assesment of cancer therapy-taxane (FACT-taxane). Cancer 2003; 98: 822-831.
16. Yellen SB, Cella DF, Webster K et al. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage 1997; 13: 63-74.
17. Berger VW, Ivanova A, Knoll M. Minimizing predictability while retaining balance through the use of less restrictive randomization procedures. Stat Med 2003; 22: 3017-3028.
18. Smith IE, O'Brien ME, Talbot DC et al. Duration of chemotherapy in advanced non-small-cell lung cancer: A randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. J Clin Oncol 2001; 19: 1336-1343.
19. Andresen O, Sorenson S, Bergman B et al. Duration of chemotherapy and survival in advanced non-small cell lung cancer (NSCLC). A multicenter, prospective randomised study. Lung Cancer 2003; 41: S28.
20. DePierre A, Quoix E, Mercier M et al. Maintenance chemotherapy in advanced non-small cell lung cancer (NSCLC): A randomized study of vinorelbine (V) versus observation (OB) in patients (Pts) responding to induction therapy (French Cooperative Oncology Group). Proc Am Soc Clin Oncol 2001; 20: 309a.
21. Lilenbaum RC, Herndon JE, 2nd, List MA et al. Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: The cancer and leukemia group B (study 9730). J Clin Oncol 2005; 23: 190-196.